| Date Filed | Type | Description |
| 10/12/2023 |
8-K
| Quarterly results |
| 08/11/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/10/2023 |
8-K
| Quarterly results |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/21/2023 |
8-K
| Quarterly results |
| 05/26/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 05/11/2023 |
4
| WIDDER KENNETH J (Director) has filed a Form 4 on Evoke Pharma Inc|
Txns:
| Granted 14,250 options to buy
@ $2.12, valued at
$30.2k
|
|
| 05/11/2023 |
4
| REED VICKIE S (Director) has filed a Form 4 on Evoke Pharma Inc|
Txns:
| Granted 15,000 options to buy
@ $2.12, valued at
$31.8k
|
|
| 05/11/2023 |
4
| Hill Malcolm R (Director) has filed a Form 4 on Evoke Pharma Inc|
Txns:
| Granted 14,625 options to buy
@ $2.12, valued at
$31k
|
|
| 05/11/2023 |
4
| GARNER CAM L (Director) has filed a Form 4 on Evoke Pharma Inc|
Txns:
| Granted 17,750 options to buy
@ $2.12, valued at
$37.6k
|
|
| 05/11/2023 |
4
| Brady Todd C (Director) has filed a Form 4 on Evoke Pharma Inc|
Txns:
| Granted 14,625 options to buy
@ $2.12, valued at
$31k
|
|
| 05/11/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/09/2023 |
8-K
| Other Events Interactive Data |
| 05/01/2023 |
8-K
| Quarterly results |
| 04/20/2023 |
8-K
| Quarterly results |
| 04/06/2023 |
8-K
| Other Events Interactive Data |
| 03/29/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/29/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 03/29/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/23/2023 |
8-K
| Other Events Interactive Data |
| 03/21/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/21/2023 |
8-K
| Quarterly results|
Docs:
|
"Evoke Pharma Reports Fourth Quarter and Full Year 2022 Financial Results Fiscal year 2022 net product sales from prescriptions increased by 179% to $2.5 million versus 2021 Patient enrollment increased by 149% compared with 2021 SOLANA BEACH, Calif., March 21, 2023 -- Evoke Pharma, Inc. , a specialty pharmaceutical company focused primarily on treatments for gastrointestinal diseases with an emphasis on GIMOTI® nasal spray, today announced its financial results for the fourth quarter and full year ended December 31, 2022, and recent corporate developments. “Evoke’s fiscal year 2022 was a period of tremendous growth and progress on several key fronts. Year-over-year revenues, new prescribers, prescription fills, and patient enrollments showed significant improvement in 2022 compared ..." |
|
| 03/17/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 02/13/2023 |
8-K
| Quarterly results |
| 02/10/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/10/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/10/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/30/2023 |
8-K
| Other Events Interactive Data |
| 11/30/2022 |
8-K
| Quarterly results |
| 11/09/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/09/2022 |
8-K
| Quarterly results |
| 09/20/2022 |
8-K
| Other Events Interactive Data |
| 08/26/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 08/10/2022 |
8-K
| Quarterly results |
|